000			05138nam a22004695i 4500
999			_c120514 _d120514 _x1
001			120514
003			ES-MaUEC
005			20230102114046.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200427s2020 gw a o |||| 0|eng d
020			_a9783030449032
024	7		_a10.1007/978-3-030-44903-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQH608 _b2020 EB
245	0	0	_aSenolytics in Disease, Ageing and Longevity / _cedited by Daniel Muñoz-Espin, Marco Demaria.
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (X, 222 páginas) _b21 ilustraciones, 16 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aHealthy Ageing and Longevity _x2199-9007 _v11
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aPart I: Origins and Development of Senotherapies -- Chapter 1. Senolytic drug development -- Chapter 2. Discovery of Senolytics and the pathway to early phase clinical trials -- Part II: The Impact of Senotherapies: from Regeneration to Aging -- Chapter 3. Interconnection between cellular senescence, regeneration and ageing in salamanders -- Chapter 4. Senolytics target senescent cells and improve aging and age-related diseases -- Chapter 5. Senotherapy of cancer -- Part III: Understanding and Targeting the Senescent Surfaceome -- Chapter 6. Targeted senolytic strategies based on the senescent surfaceome -- Chapter 7. Senolysis and senostasis through the plasma membrane -- Part IV: Novel Senescence-Associated Markers and Targets -- Chapter 8. In situ detection of miRNAs in senescent cells in archival material -- Chapter 9. Novel probes and carriers to target senescent cells -- Chapter 10. Potential applications of aptamers for targeting senescent cells -- Chapter 11. Mitochondria: potential targets for interventions to counteract senescence.
520	3		_aThis book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners.
988			_aSpringer_Biomedlife_23062020
650		7	_aMuerte celular _2embne _9160237
650		7	_aCitología _2embne _9139477
650		7	_aBiología molecular _2embne _9139103
700	1		_aMuñoz-Espin, Daniel _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aDemaria, Marco _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n2019182023 _1http://viaf.org/viaf/8446154983562767860009
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729
776	0	8	_iPrinted edition: _z9783030449025
776	0	8	_iPrinted edition: _z9783030449049
776	0	8	_iPrinted edition: _z9783030449056
830		0	_aHealthy Ageing and Longevity, _x2199-9007 ; _v11
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-44903-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b07/2020 _dz _eo _zSI